Robert Dwyer Nolan

NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom.

Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Epistem Ltd. engages in the provision of research solutions. It offers laser capture microdissection, imaging; microbiome, gene expression, NGS, DNA genotyping, and plucked hair analysis; Histology and IHC, and analytical services. The company was founded by Christopher Stanislaus Potten, Catherine Booth and Julie Tudor in 2000 and is headquartered in Manchester, the United Kingdom.